Table III.
AFB1-treateda |
Controlb |
|||||||
---|---|---|---|---|---|---|---|---|
Neonatal |
Adult |
Neonatal |
Adult |
|||||
Type of mutation | Number | % | Number | % | Number | % | Number | % |
G:C → C:G | 5 | 7 | 1 | 2 | 3 | 5 | 3 | 9 |
G:C → A:T | 6 | 9 | 18 | 32 | 28 | 50 | 13 | 41 |
G:C → T:A | 53 | 76 | 28 | 51 | 12 | 21 | 2 | 6 |
A:T → T:A | 1 | 1 | 2 | 4 | 0 | 0 | 0 | 0 |
A:T → C:G | 0 | 0 | 0 | 0 | 5 | 9 | 3 | 9 |
A:T → G:C | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 9 |
Frameshift | 3 | 4 | 4 | 7 | 7 | 13 | 8 | 25 |
Tandem | 2 | 3 | 2 | 4 | 0 | 0 | 0 | 0 |
Total mutants screened | 70 | 100 | 55 | 100 | 56 | 100 | 32 | 100 |
The mutational spectra for AFB1-treated neonatal and adult mice were significantly different from their respective concurrent controls (P < 0.0001). Also, there was a significant difference between the AFB1-treated neonatal and adult mice (P < 0.01). There was no significant difference between the two control groups.
Data for controls were obtained from our previous study [Chen et al., 2005]. The control animals were treated with DMSO at 2 μl/g body weight.